Raymond James Financial Inc. Acquires New Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Raymond James Financial Inc. acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 481,989 shares of the biopharmaceutical company's stock, valued at approximately $14,508,000. Raymond James Financial Inc. owned about 0.31% of TG Therapeutics at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Bleakley Financial Group LLC purchased a new stake in TG Therapeutics in the fourth quarter valued at $245,000. Castellan Group acquired a new stake in shares of TG Therapeutics in the 4th quarter valued at about $8,539,000. Barclays PLC grew its stake in TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock worth $8,117,000 after buying an additional 158,323 shares during the last quarter. JPMorgan Chase & Co. grew its stake in TG Therapeutics by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock worth $16,859,000 after buying an additional 270,286 shares during the last quarter. Finally, Stratos Wealth Advisors LLC acquired a new position in TG Therapeutics during the fourth quarter worth approximately $241,000. Institutional investors and hedge funds own 58.58% of the company's stock.

Analyst Upgrades and Downgrades

TGTX has been the topic of a number of research reports. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, TG Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Stock Performance

Shares of TGTX stock traded up $1.03 during mid-day trading on Friday, hitting $41.33. The stock had a trading volume of 1,464,365 shares, compared to its average volume of 3,085,138. The firm has a market cap of $6.56 billion, a PE ratio of -413.26 and a beta of 2.14. The company's 50-day simple moving average is $37.18 and its 200-day simple moving average is $32.45. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $43.32.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. Sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.